公开(公告)号：EP3080602B1

公开(公告)日：2018-11-28

申请号：EP14868919.3

申请日：2014-12-12

申请人： The Brigham and Women's Hospital, Inc.

发明人： QUINTANA, Francisco J. ,  MAYO, Lior ,  WEINER, Howard ,  HALSE, Reza

IPC分类号： G01N33/48 ,  A61P25/00

CPC分类号： G01N33/564 ,  A61K31/445 ,  A61K31/5375 ,  A61K31/713 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/30 ,  G01N2400/00 ,  G01N2405/00 ,  G01N2800/285 ,  G01N2800/50

摘要： As described herein, lactosylceramide (LacCer) levels are up-regulated in the CNS during chronic experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). LacCer acts in an autocrine manner to trigger transcriptional programs that promote the recruitment and activation of CNS infiltrating monocytes and microglia, and neurodegeneration. In addition, increased B4GALT6 expression and LacCer levels were detected in CNS MS lesions in human patients. Finally, the inhibition of LacCer synthesis suppressed local CNS innate immunity and neurodegeneration in EAE, and interfered with the activation of human astrocytes in vitro. Thus, B4GALT6 is a therapeutic target for MS and other neuroinflammatory disorders.

公开(公告)号：EP3373007A1

公开(公告)日：2018-09-12

申请号：EP17159341.1

申请日：2017-03-06

申请人： Metabolomic Discoveries GmbH ,  Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. ,  Universitätsklinikum Hamburg-Eppendorf

发明人： Stoessel, Daniel ,  Schauer, Nicolas ,  Pless, Ole ,  Friese, Manuel

IPC分类号： G01N33/564

CPC分类号： G01N33/5091 ,  G01N33/564 ,  G01N2570/00 ,  G01N2800/285 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/60

摘要： The present invention relates to a method of diagnosing primary progressive multiple sclerosis (PPMS) in a patient suspected of having PPMS. Further, the present invention relates to a method of determining the course of PPMS in a patient having PPMS. Furthermore, the present invention relates to a method of determining the severity of PPMS in a patient suspected of having PPMS. It also relates to the use of at least one metabolite for diagnosing PPMS in a patient suspected of having PPMS, for determining the course of PPMS in a patient having PPMS, or for determining the severity of PPMS in a patient suspected of having PPMS. In addition, it relates to a kit for diagnosing PPMS in a patient suspected of having PPMS, for determining the course of PPMS in a patient having PPMS, or for determining the severity of PPMS in a patient suspected of having PPMS.

公开(公告)号：EP2872486B1

公开(公告)日：2018-09-12

申请号：EP13750947.7

申请日：2013-07-16

申请人： Yeda Research and Development Co. Ltd.

发明人： MARGULIES, David ,  ROUT , Bhimsen

IPC分类号： C07D211/60 ,  A61B5/00 ,  G01N22/00 ,  G01J3/44

CPC分类号： C07F5/025 ,  C07D211/60 ,  C09B62/44 ,  G01N33/582 ,  G01N2400/00 ,  G01N2458/30 ,  G01N2800/042 ,  G01N2800/065 ,  G01N2800/067 ,  G01N2800/285

摘要： The present invention is directed to a multi-sensor array compound including at least three chromophores, at least one receptor and an anchor. Contacting the compound of this invention with an analyte (such as carbohydrate) forms a complex with unique optical signature. The unique optical signature allows differentiating between carbohydrates, diagnosing diseases associated with the carbohydrate, and encoding information in an encoding system.

公开(公告)号：EP3353329A1

公开(公告)日：2018-08-01

申请号：EP16849780.8

申请日：2016-09-23

申请人： Oklahoma Medical Research Foundation ,  The Board of Trustees of the Leland Stanford Junior University

发明人： AXTELL, Robert, C. ,  STEINMAN, Lawrence

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： G01N33/6896 ,  A61K38/215 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/565 ,  G01N2800/285 ,  G01N2800/52 ,  G06F19/00 ,  G06F19/18 ,  G06F19/24 ,  G16H50/20 ,  Y02A90/26

摘要： Disclosed herein are methods in which an individual with multiple sclerosis (MS) can be classified into one of six subject groups, each subject group predictive for the patient's responsiveness to an interferon-β (IFN-β) therapy. The individual with MS can be classified according to the individual's serum marker levels, e.g., at baseline or following treatment with therapy. Depending on the classification, the individual with MS can be treated with standard therapies (e.g. IFN-β) or one or more alternative therapies with or without IFN-β.

公开(公告)号：EP2910945B1

公开(公告)日：2018-07-18

申请号：EP15157618.8

申请日：2009-09-30

申请人： Case Western Reserve University

发明人： Wang, Yanming ,  Wu, Chunying

IPC分类号： A61K51/04 ,  A61K49/10 ,  G01N33/48

CPC分类号： A61K49/085 ,  A61K49/0021 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/10 ,  A61K51/04 ,  G01N33/92 ,  G01N2405/10 ,  G01N2800/285

摘要： A molecular probe for labeling myelin includes a fluorescent trans-stilbene derivative.

公开(公告)号：EP3306316A1

公开(公告)日：2018-04-11

申请号：EP16193119.1

申请日：2016-10-10

申请人： Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts

发明人： ZUR HAUSEN, Harald ,  DE VILLIERS, Ethel-Michele ,  BUND, Timo ,  EILEBRECHT, Sebastian

IPC分类号： G01N33/50 ,  G01N33/53 ,  G01N33/564

CPC分类号： G01N33/53 ,  G01N33/502 ,  G01N33/564 ,  G01N2800/285

摘要： Described is a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) an increased amount of Rep protein or fragments thereof in a sample from a subject as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is a MSBI1 Rep or MSBI2 Rep.

摘要翻译： 描述了用于诊断多发性硬化症（MS）的DNA复制相关（Rep）蛋白，其中（a）与来自受试者的样品中的量相比，来自受试者的样品中Rep蛋白或其片段的量增加 对照样本; 或与对照样品中的量相比，来自受试者的样品中抗原与抗原的量增加与MS的诊断相关，其中所述Rep蛋白是MSBI1 Rep或MSBI2 Rep。

公开(公告)号：EP3242685A1

公开(公告)日：2017-11-15

申请号：EP16734863.0

申请日：2016-01-08

申请人： AdAlta Pty Ltd

发明人： FOLEY, Michael ,  POW, Andrew ,  GRIFFITHS, Katherine ,  COBB, Samantha ,  VIDUKA, Katerina

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61P9/10 ,  G01N33/574

CPC分类号： C07K17/02 ,  A61K38/2228 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56988 ,  G01N33/574 ,  G01N2333/521 ,  G01N2800/285 ,  G01N2800/323

摘要： The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.

公开(公告)号：EP2989468B1

公开(公告)日：2017-11-08

申请号：EP14720104.0

申请日：2014-04-25

申请人： Synthon B.V.

发明人： KOLEN, Sebastianus Martinus Henricus ,  WEIJTS, Francisca Antoinette Adriana

IPC分类号： G01N33/68 ,  G01N33/50

CPC分类号： G01N33/5011 ,  G01N33/5023 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/6863 ,  G01N2333/57 ,  G01N2333/7155 ,  G01N2800/285

摘要： The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon gamma (IFN³), exposing said cells to said batch of glatiramer acetate, and determining determining the number of metabolically active cells induced by glatiramer acetate.

公开(公告)号：EP3231789A1

公开(公告)日：2017-10-18

申请号：EP17168303.0

申请日：2007-05-24

申请人： Phenomenome Discoveries Inc.

发明人： COOK, Lisa ,  GOODENOWE, Dayan

IPC分类号： C07C59/62 ,  C07C235/08 ,  C07C59/105 ,  C07D311/72 ,  C07F9/09 ,  C07F9/10 ,  G01N33/483 ,  G01N33/487 ,  G01N33/50

CPC分类号： C07F9/103 ,  C07C59/46 ,  C07C59/62 ,  C07C235/08 ,  C07C2601/16 ,  C07D311/72 ,  C07F9/106 ,  G01N33/53 ,  G01N33/564 ,  G01N33/6848 ,  G01N33/6893 ,  G01N33/72 ,  G01N2800/28 ,  G01N2800/285 ,  G01N2800/56

摘要： The present invention describes methods for the diagnosis and differential diagnosis of the different forms of multiple sclerosis. The methods measure the intensities of specific small molecules called metabolites in samples from patients with clinically diagnosed relapsing-remitting or primary-progressive forms of multiple sclerosis and compare these intensities to the intensities observed in a population of healthy individuals, thus identifying markers of multiple sclerosis. A method is also provided for the differential diagnosis of subjects afflicted with relapsing-remitting multiple sclerosis from secondary-progressive multiple sclerosis.

摘要翻译： 本发明描述了用于不同形式的多发性硬化症的诊断和鉴别诊断的方法。 这些方法测量来自临床诊断为复发 - 缓解型或原发进展型多发性硬化症患者的样品中称为代谢物的特定小分子的强度，并将这些强度与健康个体中观察到的强度进行比较，从而鉴定多发性硬化症的标志物 。 还提供了用于鉴别复发 - 缓解型多发性硬化症与继发性进行性多发性硬化症的受试者的鉴别诊断的方法。

公开(公告)号：EP3217973A1

公开(公告)日：2017-09-20

申请号：EP15858738.6

申请日：2015-11-12

申请人： The Brigham and Women's Hospital, Inc.

发明人： FAREZ, Mauricio ,  QUINTANA, Francisco J. ,  CORREALE, Jorge

IPC分类号： A61K31/405 ,  A61K31/4045 ,  A61P25/28 ,  C07D209/16

CPC分类号： A61K31/165 ,  A61K31/202 ,  A61K31/343 ,  A61K31/4045 ,  A61K45/06 ,  C07D209/16 ,  G01N33/74 ,  G01N2800/285 ,  G01N2800/50 ,  G01N2800/52

摘要： Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (MS) in a subject who has MS, comprising administering a melatonin agonist to a subject.

摘要翻译： 用于治疗患有MS的受试者中多发性硬化症（MS）的季节性恶化或降低发展风险的方法，所述方法包括将褪黑激素激动剂施用于受试者。